Skip to main content

About Orphalan

At Orphalan we identify, develop and provide access to innovative treatments for patients with rare diseases.

We are an international orphan drug development and commercialization company headquartered in Paris.

Founded in 2011, we develop and deliver innovative therapies for people living with rare and debilitating diseases. Our trientine tetrahydrochloride product has been approved for the treatment of Wilson disease and is available in 30+ countries, branded as Cuprior® / Cuvrior®.

Learn More

Our Approach

Our Commitment

Our Values


Making a meaningful difference to people living with rare diseases, who have limited or no options for treatment.


Persevering relentlessly and exercising patience to find the right solution for patients with unaddressed medical needs.


Connecting our expertise, patient insights and innovative thinking to work together in developing treatments to improve patients' lives.


Using the best experts, scientists and academic institutions to further pharmaceutical development, combining clinical evidence with experience.


Moving and adapting quickly to solve any challenge that may arise and proactively offering services and solutions for patients who need them.

Our Board of Directors


Naseem Amin

Chief Executive Officer

Chahra Louafi

Board Observer

Shahzad Malik

Chairman of the Board

Jean-Francois Morin

Non Executive Director

Kaasim Mahmood

Non Executive Director

Emmanuelle Voisin

Non-Executive Director

Our Leadership Team


Naseem Amin

Chief Executive Officer

Massimo Boriero

Head of Europe

Margot Pisani

Head commercial hub Malta

Angelita Briffa

Chief Accounting Officer

Sandra Bensoussan

Chief Legal Officer

Sujatha Karoor

Chief R&D Officer

Geraldine Van Den Broek

Head of Corporate Affairs & Project Management

Omar Camille Kamlin

Senior Medical Director

Tim Jenkins

Chief Development Officer

Chris Homan

Chief Quality Officer

Dmitry Paramonov

Head of North America

Ivo Sulovsky

Head of Portfolio Strategy and Planning

John Fatuhi

Head of International Markets

Our Investors

Find out more

Our Research